美国食品药品监督管理局（FDA）已决定推迟对赛诺菲安万特旗下糖尿病治疗药物Tzield以及Disc Medicine公司血液疾病治疗药物的审评时间表。相关内部文件显示，监管机构需要更多时间完成对这两款创新疗法的评估工作。
此次审评周期延长意味着两家公司需要等待更长时间才能获得最终审批决定。业内观察人士指出，FDA的审评延期通常涉及对补充数据或生产信息的进一步核查，这属于新药审评流程中的常规环节。
对于赛诺菲安万特而言，Tzield作为其糖尿病管线的重要候选药物，审评进度的变化将直接影响该产品的上市时间表。而Disc Medicine的血液疾病药物同样面临关键审评节点，此次延期将对公司的研发里程碑产生连锁影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.